产品：诺和力^®（利拉鲁肽注射液）

介绍：

活性成分：利拉鲁肽；

本品适用于成人2型糖尿病患者控制血糖：

适用于单用二甲双胍或磺脲类药物最大可耐受剂量治疗后血糖仍控制不佳的患者，与二甲双胍或磺脲类药物联合应用；

适用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件(心血管死亡、非致死性心肌梗死或非致死性卒中）风险。

诺和力®（利拉鲁肽注射液）是全球首个人胰高糖素样肽-1（GLP-1）类似物，与人体内天然的GLP-1同源性达到97%。

2020年5月，诺和力®心血管适应症在中国获批，在改善成人2型糖尿病患者的血糖控制之外，还可用于降低伴有心血管疾病的2型糖尿病成人患者的主要心血管不良事件(心血管死亡、非致死性心肌梗死或非致死性卒中）风险，心血管适应症的获批具有划时代的临床意义。

诺和力^®具有下列显著特点：

诺和力®（利拉鲁肽注射液）是第一个证实可减少心血管死亡风险的GLP-1RA，强效降糖达1.6%，低血糖风险极低，同时显著降低体重，改善胰岛素抵抗。

2021年，诺和力®（利拉鲁肽注射液）在中国上市十周年，十年循证历程助力我国2型糖尿病管理理念的不断革新。

Product: Victoza® (Liraglutide injection)

Introduction:

Active ingredient: Liraglutide;

This product is suitable for adult patients with type 2 diabetes to control blood glucose:

It is suitable for patients whose blood glucose is still poorly controlled after the treatment with the maximum tolerable dose of metformin or sulfonylurea alone, and is used in combination with metformin or sulfonylurea;

It is applicable to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adult patients with type 2 diabetes with cardiovascular disease.

Victoza® (liraglutide injection) is the first human glucagon like peptide-1 (GLP-1) analog in the world, with 97% homology with natural GLP-1 in human body.

In May 2020, Victoza® Cardiovascular indications have been approved in China. In addition to improving blood glucose control in adult patients with type 2 diabetes, they can also be used to reduce the risk of major cardiovascular adverse events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adult patients with type 2 diabetes associated with cardiovascular disease. The approval of cardiovascular indications has epoch-making clinical significance.

Victoza® It has the following remarkable characteristics:

Victoza® (Liraglutide injection) is the first GLP-1 RA that has been proved to reduce the risk of cardiovascular death. It has a strong hypoglycemic effect of 1.6%. The risk of hypoglycemia is extremely low. At the same time, it can significantly reduce body weight and improve insulin resistance.

In 2021, Victoza® (Liraglutide injection) has been listed in China for ten years, and the ten-year evidence-based process has helped to continuously innovate the management concept of type 2 diabetes in China.